Background: Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83–120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183–120and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation. Objective: Validation of the diagnostic potential of anti-KIR4.183–120antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases. Methods: Analysis of anti-KIR4.183–120antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry. Results: We found antibodies to KIR4.183–120only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies. Conclusion: Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183–120auto-antibodies as a reliable biomarker in MS.

Marino, M., Frisullo, G., Di Sante, G., Samengo, D. M., Provenzano, C., Mirabella, M., Pani, G., Ria, F., Bartoccioni, E., Low reliability of anti-KIR4.183â 120peptide auto-antibodies in multiple sclerosis patients, <<MULTIPLE SCLEROSIS>>, 2018; 24 (7): 910-918. [doi:10.1177/1352458517711275] [http://hdl.handle.net/10807/117571]

Low reliability of anti-KIR4.183–120peptide auto-antibodies in multiple sclerosis patients

Marino, Mariapaola;Frisullo, Giovanni;Di Sante, Gabriele;Samengo, Daniela Maria;Provenzano, Carlo;Mirabella, Massimiliano;Pani, Giovambattista;Ria, Francesco;Bartoccioni, Emanuela
2018

Abstract

Background: Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83–120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183–120and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation. Objective: Validation of the diagnostic potential of anti-KIR4.183–120antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases. Methods: Analysis of anti-KIR4.183–120antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry. Results: We found antibodies to KIR4.183–120only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies. Conclusion: Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183–120auto-antibodies as a reliable biomarker in MS.
Inglese
Marino, M., Frisullo, G., Di Sante, G., Samengo, D. M., Provenzano, C., Mirabella, M., Pani, G., Ria, F., Bartoccioni, E., Low reliability of anti-KIR4.183â 120peptide auto-antibodies in multiple sclerosis patients, <<MULTIPLE SCLEROSIS>>, 2018; 24 (7): 910-918. [doi:10.1177/1352458517711275] [http://hdl.handle.net/10807/117571]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/117571
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact